MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from reverse
recapitalization and pipe...
$373,457K
Issuance of series b
redeemable convertible...
$22,222K
Maturities of marketable
securities
$157,859K
Exercise of common stock
options for cash
$45K
Net cash provided by
financing activities
$383,402K
Net cash provided by
(used in) investing...
$73,328K
Canceled cashflow
$12,322K
Canceled cashflow
$84,531K
Net increase in
cash, cash...
$342,836K
Canceled cashflow
$113,894K
Payment of deferred
transaction costs
$12,322K
Accrued research and
development liabilities
$17,675K
Fair value of common
stock issued to...
-$7,769K
Stock-based compensation
$5,873K
Accrued compensation
and benefits
$1,925K
Change in fair value of
participation right liability
$725K
Amortization of right-of-use
assets
$330K
Depreciation of property and
equipment
$280K
Other accrued
liabilities
$74K
Purchases of marketable
securities
$83,925K
Purchases of property and
equipment
$606K
Net cash used in
operating activities
-$113,894K
Canceled cashflow
$34,651K
Net loss
-$134,044K
Other non-current
assets
$7,581K
Prepaid expense and
other currents assets
$3,417K
Accounts payble
-$1,840K
Net accretion of
premiums on marketable...
$1,260K
Balances due to and from
related parties
$254K
Accrued professional
services
-$102K
Operating lease
liabilities
-$47K
Back
Back
Cash Flow
source: myfinsight.com
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)